Sanofi (SNY) 10-Year Financial Performance & Capital Metrics

SNY •

HealthcareLarge PharmaVaccines and plasma-derived therapies

AboutSanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.Show more

Revenue $46.72B +5.5%
EBITDA $9.55B -11.8%
Net Income $7.81B +40.5%
EPS (Diluted) 2.03 -7.3%
Gross Margin 72.34% +3.1%
EBITDA Margin 20.45% -16.4%
Operating Margin 13.58% -17.1%
Net Margin 16.72% +33.2%
ROE 10.45% +43.0%
ROIC 5.46% -13.3%
Debt/Equity 0.30 +32.1%
Interest Coverage 11.73 +0.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 19.0% free cash flow margin
✓13 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.5% through buybacks
✓Healthy 5Y average net margin of 15.8%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.97%

5Y4.57%

3Y4.82%

TTM8.91%

Profit (Net Income) CAGR

10Y6.19%

5Y-8.67%

3Y-2.27%

TTM40.52%

EPS CAGR

10Y2.16%

5Y-16.19%

3Y-13.9%

TTM-14.64%

ROCE

10Y Avg7.64%

5Y Avg7.71%

3Y Avg6.7%

Latest6.28%

Peer Comparison

Vaccines and plasma-derived therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.35B	9.10	33.54	9.41%	4.96%	4.92%	26.64%	1.17
PFEPfizer Inc.	157.21B	27.65	20.33	-1.65%	12.42%	8.35%
SNYSanofi	117.53B	48.66	20.32	5.49%	16.72%	10.9%	8.92%	0.30
MRKMerck & Co., Inc.	307.22B	123.78	17.00	1.31%	28.08%	35.17%
GSKGSK plc	118.65B	59.13	16.16	1.83%	17.86%	35.83%	6.6%	1.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	34.7B	36.22B	35.68B	37.63B	37.37B	39.17B	40.56B	41.62B	44.29B	46.72B
Revenue Growth %	-0.47%	4.4%	-1.5%	5.48%	-0.7%	4.83%	3.54%	2.61%	6.41%	5.49%
Cost of Goods Sold+	10.7B	11.61B	11.44B	11.98B	12.16B	12.26B	11.88B	12.63B	13.21B	12.92B
COGS % of Revenue	30.84%	32.06%	32.05%	31.83%	32.54%	31.28%	29.29%	30.34%	29.82%	27.66%
Gross Profit+	24B	24.61B	24.24B	25.65B	25.21B	26.92B	28.68B	28.99B	31.08B	33.79B
Gross Margin %	69.16%	67.94%	67.95%	68.17%	67.46%	68.72%	70.71%	69.66%	70.18%	72.34%
Gross Profit Growth %	0.22%	2.55%	-1.49%	5.82%	-1.72%	6.78%	6.53%	1.08%	7.21%	8.73%
Operating Expenses+	17.46B	18.8B	19.57B	22.6B	11.1B	18.79B	18.52B	22.03B	23.83B	27.45B
OpEx % of Revenue	50.33%	51.91%	54.84%	60.06%	29.7%	47.97%	45.65%	52.93%	53.81%	58.76%
Selling, General & Admin	9.48B	10.07B	9.86B	9.88B	9.39B	9.55B	8.74B	8.93B	9.18B	9.54B
SG&A % of Revenue	27.32%	27.81%	27.63%	26.27%	25.13%	24.39%	21.55%	21.46%	20.74%	20.43%
Research & Development	5.17B	5.47B	5.89B	6.02B	5.53B	5.69B	6.5B	6.51B	7.39B	7.84B
R&D % of Revenue	14.91%	15.11%	16.52%	16%	14.8%	14.53%	16.03%	15.64%	16.7%	16.79%
Other Operating Expenses	2.81B	3.26B	3.81B	6.7B	-3.82B	3.55B	3.28B	6.59B	7.25B	10.06B
Operating Income+	6.53B	5.8B	4.68B	3.05B	14.11B	8.13B	10.16B	6.96B	7.25B	6.34B
Operating Margin %	18.82%	16.02%	13.11%	8.11%	37.77%	20.74%	25.05%	16.72%	16.38%	13.58%
Operating Income Growth %	16.13%	-11.13%	-19.43%	-34.75%	362.57%	-42.42%	25.06%	-31.51%	4.2%	-12.52%
EBITDA+	9.83B	9.49B	8.96B	10.5B	17.78B	11.48B	13.27B	11.39B	10.84B	9.55B
EBITDA Margin %	28.34%	26.2%	25.1%	27.89%	47.59%	29.3%	32.72%	27.37%	24.47%	20.45%
EBITDA Growth %	-0.69%	-3.48%	-5.64%	17.21%	69.44%	-35.46%	15.62%	-14.17%	-4.84%	-11.85%
D&A (Non-Cash Add-back)	3.3B	3.69B	4.28B	7.45B	3.67B	3.35B	3.11B	4.43B	3.59B	3.21B
EBIT	6.6B	5.95B	4.9B	3.22B	14.21B	8.19B	10.4B	6.96B	7.45B	9.47B
Net Interest Income+	-340.47M	-279.47M	-412.12M	-446.57M	-396.41M	-374.24M	-215.84M	17.68M	-165.04M	-162.33M
Interest Income	59.03M	53.97M	74.37M	89.71M	34.43M	3.13M	168.96M	530.5M	457.53M	378.45M
Interest Expense	399.5M	333.43M	486.48M	536.27M	430.84M	377.37M	384.8M	512.82M	622.58M	540.78M
Other Income/Expense	-720M	-188M	228M	-44M	24M	-289M	-170M	-845M	-494M	-324M
Pretax Income+	5.81B	5.62B	4.9B	3.01B	14.14B	7.84B	9.99B	6.12B	6.76B	6.02B
Pretax Margin %	16.75%	15.5%	13.75%	7.99%	37.83%	20.01%	24.63%	14.69%	15.26%	12.89%
Income Tax+	1.32B	1.72B	481M	121M	1.81B	1.56B	1.91B	1.02B	1.2B	1.04B
Effective Tax Rate %	81.04%	149.86%	87.81%	91.59%	86.96%	79.41%	83.78%	88.31%	82.27%	129.78%
Net Income+	4.71B	8.42B	4.31B	2.75B	12.29B	6.22B	8.37B	5.4B	5.56B	7.81B
Net Margin %	13.57%	23.24%	12.07%	7.32%	32.9%	15.89%	20.64%	12.98%	12.55%	16.72%
Net Income Growth %	9.84%	78.72%	-48.84%	-36.04%	346.41%	-49.38%	34.52%	-35.49%	2.96%	40.52%
Net Income (Continuing)	4.49B	3.89B	4.42B	2.89B	12.33B	6.28B	8.08B	5.1B	5.55B	4.98B
Discontinued Operations	314M	4.64B	-13M	-101M	0	0	401M	338M	64M	2.87B
Minority Interest	170M	169M	159M	174M	146M	350M	368M	313M	350M	334M
EPS (Diluted)+	1.83	3.36	1.73	1.14	4.91	2.49	3.18	2.15	2.19	2.03
EPS Growth %	11.59%	83.61%	-48.51%	-34.1%	330.7%	-49.29%	27.71%	-32.39%	1.86%	-7.31%
EPS (Basic)	1.83	1.50	1.73	1.14	4.91	2.49	3.19	2.15	2.19	2.03
Diluted Shares Outstanding	2.57B	2.51B	2.49B	2.5B	2.51B	2.5B	2.5B	2.51B	2.5B	2.44B
Basic Shares Outstanding	2.57B	2.51B	2.49B	2.5B	2.51B	2.5B	2.5B	2.5B	2.5B	2.44B
Dividend Payout Ratio	79.83%	44.08%	87.62%	139.22%	32.02%	64.41%	49.79%	82.48%	84.6%	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	26.69B	26.35B	24.58B	28.61B	33.7B	30.56B	34.03B	30.66B	42.59B	30.95B
Cash & Short-Term Investments	10.38B	10.31B	6.92B	9.74B	13.91B	10.1B	12.74B	8.71B	7.93B	7.66B
Cash Only	10.27B	10.31B	6.92B	9.74B	13.91B	10.1B	12.74B	8.71B	7.44B	7.66B
Short-Term Investments	108M	0	0	0	0	0	0	0	486M	0
Accounts Receivable	9.05B	8.68B	9.35B	10.08B	9.95B	9.79B	10.75B	11.04B	10.63B	396.83M
Days Sales Outstanding	95.21	87.42	95.61	97.8	97.22	91.19	96.7	96.82	87.6	3.1
Inventory	6.89B	6.82B	7.48B	7.99B	8.35B	8.71B	8.96B	9.67B	9.43B	22.69B
Days Inventory Outstanding	235.08	214.29	238.66	243.58	250.72	259.57	275.24	279.39	260.68	640.89
Other Current Assets	31M	210M	363M	299M	958M	1.35B	870M	471M	13.71B	208.17M
Total Non-Current Assets+	77.98B	73.46B	86.83B	84.13B	80.71B	89.68B	92.7B	95.81B	90.21B	95.85B
Property, Plant & Equipment	10.02B	9.58B	9.65B	11.02B	10.56B	11.98B	11.68B	11.81B	11.6B	11.51B
Fixed Asset Turnover	3.46x	3.78x	3.70x	3.42x	3.54x	3.27x	3.47x	3.52x	3.82x	4.06x
Goodwill	40.29B	40.26B	44.23B	44.52B	44.36B	48.06B	49.89B	49.4B	43.38B	0
Intangible Assets	10.88B	13.08B	21.89B	16.57B	18.34B	21.41B	21.64B	24.32B	22.63B	67.56B
Long-Term Investments	5.68B	6.14B	6.17B	5.99B	2.67B	2.91B	3.22B	3.26B	3.26B	0
Other Non-Current Assets	6.45B	104M	271M	595M	600M	731M	882M	588M	1.37B	16.78B
Total Assets+	104.67B	99.81B	111.41B	112.74B	114.41B	120.24B	126.72B	126.46B	132.8B	126.81B
Asset Turnover	0.33x	0.36x	0.32x	0.33x	0.33x	0.33x	0.32x	0.33x	0.33x	0.37x
Asset Growth %	2.3%	-4.64%	11.62%	1.19%	1.49%	5.09%	5.39%	-0.2%	5.01%	-4.51%
Total Current Liabilities+	16.43B	15.46B	17.38B	20.38B	19.25B	21.3B	23.96B	24.19B	29.16B	28.35B
Accounts Payable	4.3B	4.63B	5.04B	5.31B	5.29B	6.18B	6.81B	7.33B	7.55B	22.93B
Days Payables Outstanding	146.57	145.62	160.91	161.89	158.95	184.06	209.29	211.81	208.72	647.56
Short-Term Debt	1.76B	1.27B	2.63B	4.82B	3B	3.45B	4.45B	2.32B	4.21B	4.34B
Deferred Revenue (Current)	0	0	0	0	252M	319M	264M	0	0	0
Other Current Liabilities	7.27B	6.45B	6.98B	7.66B	9.75B	10.61B	11.86B	11.57B	15.13B	64.08M
Current Ratio	1.62x	1.70x	1.41x	1.40x	1.75x	1.44x	1.42x	1.27x	1.46x	1.09x
Quick Ratio	1.20x	1.26x	0.98x	1.01x	1.32x	1.03x	1.05x	0.87x	1.14x	0.29x
Cash Conversion Cycle	183.72	156.09	173.36	179.49	188.98	166.69	162.65	164.4	139.57	-3.57
Total Non-Current Liabilities+	30.51B	26.11B	35B	33.25B	31.91B	29.92B	27.61B	27.92B	25.78B	26.74B
Long-Term Debt	16.78B	14.31B	21.99B	20.13B	19.75B	17.12B	14.86B	14.35B	11.79B	15.71B
Capital Lease Obligations	34M	20M	18M	987M	931M	1.84B	1.9B	1.75B	1.65B	1.47B
Deferred Tax Liabilities	2.29B	1.6B	3.41B	2.29B	1.77B	1.62B	1.84B	1.86B	2.17B	1.67B
Other Non-Current Liabilities	11.41B	10.18B	9.58B	9.84B	9.47B	9.34B	9B	9.96B	10.18B	7.9B
Total Liabilities	46.95B	41.57B	52.37B	53.63B	51.16B	51.21B	51.57B	52.11B	54.94B	55.1B
Total Debt+	18.58B	15.6B	24.64B	25.93B	23.68B	22.41B	21.21B	18.7B	17.91B	21.79B
Net Debt	8.31B	5.29B	17.71B	16.19B	9.76B	12.32B	8.48B	9.99B	10.46B	14.13B
Debt / Equity	0.32x	0.27x	0.42x	0.44x	0.37x	0.32x	0.28x	0.25x	0.23x	0.30x
Debt / EBITDA	1.89x	1.64x	2.75x	2.47x	1.33x	1.95x	1.60x	1.64x	1.65x	2.28x
Net Debt / EBITDA	0.84x	0.56x	1.98x	1.54x	0.55x	1.07x	0.64x	0.88x	0.97x	1.48x
Interest Coverage	16.35x	17.41x	9.61x	5.69x	32.76x	21.53x	26.41x	13.57x	11.65x	11.73x
Total Equity+	57.72B	58.24B	59.03B	59.11B	63.25B	69.03B	75.15B	74.35B	77.86B	71.71B
Equity Growth %	-0.83%	0.89%	1.37%	0.12%	7.01%	9.14%	8.87%	-1.06%	4.71%	-7.9%
Book Value per Share	22.43	23.17	23.67	23.65	25.23	27.56	30.02	29.59	31.11	29.38
Total Shareholders' Equity	57.55B	58.07B	58.88B	58.93B	63.11B	68.68B	74.78B	74.04B	77.51B	71.38B
Common Stock	2.58B	2.51B	2.5B	2.51B	2.52B	2.53B	2.52B	2.53B	2.53B	71.38B
Retained Earnings	51.48B	52.86B	53.11B	51.78B	60.15B	63.01B	66.73B	67.5B	0	0
Treasury Stock	-1.5B	-14M	-153M	-9M	-705M	-939M	-706M	-1.18B	-840M	0
Accumulated OCI	5B	2.71B	3.43B	4.51B	782M	3.55B	6.11B	4.88B	70.56B	0
Minority Interest	170M	169M	159M	174M	146M	350M	368M	313M	350M	334M

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	7.84B	7.38B	5.55B	7.74B	7.45B	10.52B	10.53B	10.26B	9.08B	10.75B
Operating CF Margin %	22.59%	20.37%	15.55%	20.58%	19.93%	26.86%	25.95%	24.65%	20.51%	23.01%
Operating CF Growth %	-12.13%	-5.86%	-24.83%	39.61%	-3.81%	41.25%	0.04%	-2.55%	-11.47%	18.38%
Net Income	4.71B	8.43B	4.31B	1.86B	12.31B	6.22B	8.37B	5.4B	5.5B	7.81B
Depreciation & Amortization	3.3B	3.69B	4.28B	7.45B	3.3B	3.35B	3.42B	3.78B	3.59B	3.21B
Stock-Based Compensation	250M	263M	284M	252M	0	244M	245M	0	0	0
Deferred Taxes	-542M	-909M	-727M	-1.75B	-221M	-356M	-578M	-1.23B	-802M	0
Other Non-Cash Items	-458M	-3.98B	-1.03B	355M	-7.62B	-349M	-225M	1.55B	1.42B	-273M
Working Capital Changes	828M	148M	-1.28B	-419M	-325M	1.41B	-707M	764M	-615M	0
Change in Receivables	168M	-529M	-35M	-462M	-134M	185M	-777M	-397M	-28M	0
Change in Inventory	-323M	-145M	-701M	-547M	-593M	-357M	-927M	-840M	-477M	0
Change in Payables	447M	577M	270M	169M	86M	451M	452M	402M	789M	0
Cash from Investing+	-2.51B	639M	-12.87B	-1.06B	3.59B	-7.3B	-2.08B	-6.2B	-4.41B	-2.45B
Capital Expenditures	-2.08B	-1.96B	-1.98B	-1.82B	-2.11B	-2.04B	-2.2B	-3.25B	-3.23B	-1.86B
CapEx % of Revenue	6%	5.4%	5.54%	4.83%	5.66%	5.22%	5.43%	7.82%	7.3%	3.98%
Acquisitions	-426M	-1.15B	-12.86B	-488M	5.03B	-5.59B	-858M	1.01B	-2.52B	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	206M	3.91B	2.1B	-94M	-113M	-68M	1.47B	-3.87B	1.35B	-589M
Cash from Financing+	-4.1B	-7.9B	3.93B	-4.19B	-6.49B	-7.06B	-5.82B	-8.05B	-5.76B	-8.21B
Debt Issued (Net)	2.29B	-2.3B	8.72B	-491M	-2.17B	-2.8B	-1.23B	-3.14B	-894M	0
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	0
Dividends Paid	-3.76B	-3.71B	-3.77B	-3.83B	-3.94B	-4.01B	-4.17B	-4.45B	-4.7B	0
Share Repurchases	-2.91B	-2.16B	-1.1B	-9M	-822M	-382M	-497M	-593M	-302M	0
Other Financing	273M	-15M	-91M	141M	441M	-48M	77M	-63M	-50M	-8.21B
Net Change in Cash	1.13B	42M	-3.39B	2.5B	4.49B	-3.82B	2.64B	-4.03B	-1.27B	216M
Free Cash Flow+	5.75B	5.42B	3.57B	5.93B	5.33B	8.48B	8.32B	8.64B	5.89B	8.89B
FCF Margin %	16.59%	14.97%	10.01%	15.75%	14.28%	21.64%	20.52%	20.76%	13.29%	19.03%
FCF Growth %	-6.39%	-5.77%	-34.17%	66.05%	-10%	58.93%	-1.82%	3.77%	-31.87%	51.07%
FCF per Share	2.24	2.16	1.43	2.37	2.13	3.38	3.32	3.44	2.35	3.64
FCF Conversion (FCF/Net Income)	1.66x	0.88x	1.29x	2.81x	0.61x	1.69x	1.26x	1.90x	1.63x	1.38x
Interest Paid	401M	347M	412M	379M	315M	334M	380M	559M	587M	0
Taxes Paid	2.1B	1.73B	2.06B	1.7B	2.05B	1.28B	2.45B	2.62B	3.29B	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	8.12%	14.52%	7.34%	4.66%	20.09%	9.41%	11.61%	7.22%	7.31%	10.45%
Return on Invested Capital (ROIC)	7.44%	6.72%	5%	3.01%	14.27%	7.9%	9.24%	6.22%	6.3%	5.46%
Gross Margin	69.16%	67.94%	67.95%	68.17%	67.46%	68.72%	70.71%	69.66%	70.18%	72.34%
Net Margin	13.57%	23.24%	12.07%	7.32%	32.9%	15.89%	20.64%	12.98%	12.55%	16.72%
Debt / Equity	0.32x	0.27x	0.42x	0.44x	0.37x	0.32x	0.28x	0.25x	0.23x	0.30x
Interest Coverage	16.35x	17.41x	9.61x	5.69x	32.76x	21.53x	26.41x	13.57x	11.65x	11.73x
FCF Conversion	1.66x	0.88x	1.29x	2.81x	0.61x	1.69x	1.26x	1.90x	1.63x	1.38x
Revenue Growth	-0.47%	4.4%	-1.5%	5.48%	-0.7%	4.83%	3.54%	2.61%	6.41%	5.49%

US Stock Screener

...

Sanofi (SNY) 10-Year Financial Performance & Capital Metrics

SNY •

HealthcareLarge PharmaVaccines and plasma-derived therapies

Revenue $46.72B +5.5%
EBITDA $9.55B -11.8%
Net Income $7.81B +40.5%
EPS (Diluted) 2.03 -7.3%
Gross Margin 72.34% +3.1%
EBITDA Margin 20.45% -16.4%
Operating Margin 13.58% -17.1%
Net Margin 16.72% +33.2%
ROE 10.45% +43.0%
ROIC 5.46% -13.3%
Debt/Equity 0.30 +32.1%
Interest Coverage 11.73 +0.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 19.0% free cash flow margin
✓13 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.5% through buybacks
✓Healthy 5Y average net margin of 15.8%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.97%

5Y4.57%

3Y4.82%

TTM8.91%

Profit (Net Income) CAGR

10Y6.19%

5Y-8.67%

3Y-2.27%

TTM40.52%

EPS CAGR

10Y2.16%

5Y-16.19%

3Y-13.9%

TTM-14.64%

ROCE

10Y Avg7.64%

5Y Avg7.71%

3Y Avg6.7%

Latest6.28%

Peer Comparison

Vaccines and plasma-derived therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.35B	9.10	33.54	9.41%	4.96%	4.92%	26.64%	1.17
PFEPfizer Inc.	157.21B	27.65	20.33	-1.65%	12.42%	8.35%
SNYSanofi	117.53B	48.66	20.32	5.49%	16.72%	10.9%	8.92%	0.30
MRKMerck & Co., Inc.	307.22B	123.78	17.00	1.31%	28.08%	35.17%
GSKGSK plc	118.65B	59.13	16.16	1.83%	17.86%	35.83%	6.6%	1.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	34.7B	36.22B	35.68B	37.63B	37.37B	39.17B	40.56B	41.62B	44.29B	46.72B
Revenue Growth %	-0.47%	4.4%	-1.5%	5.48%	-0.7%	4.83%	3.54%	2.61%	6.41%	5.49%
Cost of Goods Sold+	10.7B	11.61B	11.44B	11.98B	12.16B	12.26B	11.88B	12.63B	13.21B	12.92B
COGS % of Revenue	30.84%	32.06%	32.05%	31.83%	32.54%	31.28%	29.29%	30.34%	29.82%	27.66%
Gross Profit+	24B	24.61B	24.24B	25.65B	25.21B	26.92B	28.68B	28.99B	31.08B	33.79B
Gross Margin %	69.16%	67.94%	67.95%	68.17%	67.46%	68.72%	70.71%	69.66%	70.18%	72.34%
Gross Profit Growth %	0.22%	2.55%	-1.49%	5.82%	-1.72%	6.78%	6.53%	1.08%	7.21%	8.73%
Operating Expenses+	17.46B	18.8B	19.57B	22.6B	11.1B	18.79B	18.52B	22.03B	23.83B	27.45B
OpEx % of Revenue	50.33%	51.91%	54.84%	60.06%	29.7%	47.97%	45.65%	52.93%	53.81%	58.76%
Selling, General & Admin	9.48B	10.07B	9.86B	9.88B	9.39B	9.55B	8.74B	8.93B	9.18B	9.54B
SG&A % of Revenue	27.32%	27.81%	27.63%	26.27%	25.13%	24.39%	21.55%	21.46%	20.74%	20.43%
Research & Development	5.17B	5.47B	5.89B	6.02B	5.53B	5.69B	6.5B	6.51B	7.39B	7.84B
R&D % of Revenue	14.91%	15.11%	16.52%	16%	14.8%	14.53%	16.03%	15.64%	16.7%	16.79%
Other Operating Expenses	2.81B	3.26B	3.81B	6.7B	-3.82B	3.55B	3.28B	6.59B	7.25B	10.06B
Operating Income+	6.53B	5.8B	4.68B	3.05B	14.11B	8.13B	10.16B	6.96B	7.25B	6.34B
Operating Margin %	18.82%	16.02%	13.11%	8.11%	37.77%	20.74%	25.05%	16.72%	16.38%	13.58%
Operating Income Growth %	16.13%	-11.13%	-19.43%	-34.75%	362.57%	-42.42%	25.06%	-31.51%	4.2%	-12.52%
EBITDA+	9.83B	9.49B	8.96B	10.5B	17.78B	11.48B	13.27B	11.39B	10.84B	9.55B
EBITDA Margin %	28.34%	26.2%	25.1%	27.89%	47.59%	29.3%	32.72%	27.37%	24.47%	20.45%
EBITDA Growth %	-0.69%	-3.48%	-5.64%	17.21%	69.44%	-35.46%	15.62%	-14.17%	-4.84%	-11.85%
D&A (Non-Cash Add-back)	3.3B	3.69B	4.28B	7.45B	3.67B	3.35B	3.11B	4.43B	3.59B	3.21B
EBIT	6.6B	5.95B	4.9B	3.22B	14.21B	8.19B	10.4B	6.96B	7.45B	9.47B
Net Interest Income+	-340.47M	-279.47M	-412.12M	-446.57M	-396.41M	-374.24M	-215.84M	17.68M	-165.04M	-162.33M
Interest Income	59.03M	53.97M	74.37M	89.71M	34.43M	3.13M	168.96M	530.5M	457.53M	378.45M
Interest Expense	399.5M	333.43M	486.48M	536.27M	430.84M	377.37M	384.8M	512.82M	622.58M	540.78M
Other Income/Expense	-720M	-188M	228M	-44M	24M	-289M	-170M	-845M	-494M	-324M
Pretax Income+	5.81B	5.62B	4.9B	3.01B	14.14B	7.84B	9.99B	6.12B	6.76B	6.02B
Pretax Margin %	16.75%	15.5%	13.75%	7.99%	37.83%	20.01%	24.63%	14.69%	15.26%	12.89%
Income Tax+	1.32B	1.72B	481M	121M	1.81B	1.56B	1.91B	1.02B	1.2B	1.04B
Effective Tax Rate %	81.04%	149.86%	87.81%	91.59%	86.96%	79.41%	83.78%	88.31%	82.27%	129.78%
Net Income+	4.71B	8.42B	4.31B	2.75B	12.29B	6.22B	8.37B	5.4B	5.56B	7.81B
Net Margin %	13.57%	23.24%	12.07%	7.32%	32.9%	15.89%	20.64%	12.98%	12.55%	16.72%
Net Income Growth %	9.84%	78.72%	-48.84%	-36.04%	346.41%	-49.38%	34.52%	-35.49%	2.96%	40.52%
Net Income (Continuing)	4.49B	3.89B	4.42B	2.89B	12.33B	6.28B	8.08B	5.1B	5.55B	4.98B
Discontinued Operations	314M	4.64B	-13M	-101M	0	0	401M	338M	64M	2.87B
Minority Interest	170M	169M	159M	174M	146M	350M	368M	313M	350M	334M
EPS (Diluted)+	1.83	3.36	1.73	1.14	4.91	2.49	3.18	2.15	2.19	2.03
EPS Growth %	11.59%	83.61%	-48.51%	-34.1%	330.7%	-49.29%	27.71%	-32.39%	1.86%	-7.31%
EPS (Basic)	1.83	1.50	1.73	1.14	4.91	2.49	3.19	2.15	2.19	2.03
Diluted Shares Outstanding	2.57B	2.51B	2.49B	2.5B	2.51B	2.5B	2.5B	2.51B	2.5B	2.44B
Basic Shares Outstanding	2.57B	2.51B	2.49B	2.5B	2.51B	2.5B	2.5B	2.5B	2.5B	2.44B
Dividend Payout Ratio	79.83%	44.08%	87.62%	139.22%	32.02%	64.41%	49.79%	82.48%	84.6%	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	26.69B	26.35B	24.58B	28.61B	33.7B	30.56B	34.03B	30.66B	42.59B	30.95B
Cash & Short-Term Investments	10.38B	10.31B	6.92B	9.74B	13.91B	10.1B	12.74B	8.71B	7.93B	7.66B
Cash Only	10.27B	10.31B	6.92B	9.74B	13.91B	10.1B	12.74B	8.71B	7.44B	7.66B
Short-Term Investments	108M	0	0	0	0	0	0	0	486M	0
Accounts Receivable	9.05B	8.68B	9.35B	10.08B	9.95B	9.79B	10.75B	11.04B	10.63B	396.83M
Days Sales Outstanding	95.21	87.42	95.61	97.8	97.22	91.19	96.7	96.82	87.6	3.1
Inventory	6.89B	6.82B	7.48B	7.99B	8.35B	8.71B	8.96B	9.67B	9.43B	22.69B
Days Inventory Outstanding	235.08	214.29	238.66	243.58	250.72	259.57	275.24	279.39	260.68	640.89
Other Current Assets	31M	210M	363M	299M	958M	1.35B	870M	471M	13.71B	208.17M
Total Non-Current Assets+	77.98B	73.46B	86.83B	84.13B	80.71B	89.68B	92.7B	95.81B	90.21B	95.85B
Property, Plant & Equipment	10.02B	9.58B	9.65B	11.02B	10.56B	11.98B	11.68B	11.81B	11.6B	11.51B
Fixed Asset Turnover	3.46x	3.78x	3.70x	3.42x	3.54x	3.27x	3.47x	3.52x	3.82x	4.06x
Goodwill	40.29B	40.26B	44.23B	44.52B	44.36B	48.06B	49.89B	49.4B	43.38B	0
Intangible Assets	10.88B	13.08B	21.89B	16.57B	18.34B	21.41B	21.64B	24.32B	22.63B	67.56B
Long-Term Investments	5.68B	6.14B	6.17B	5.99B	2.67B	2.91B	3.22B	3.26B	3.26B	0
Other Non-Current Assets	6.45B	104M	271M	595M	600M	731M	882M	588M	1.37B	16.78B
Total Assets+	104.67B	99.81B	111.41B	112.74B	114.41B	120.24B	126.72B	126.46B	132.8B	126.81B
Asset Turnover	0.33x	0.36x	0.32x	0.33x	0.33x	0.33x	0.32x	0.33x	0.33x	0.37x
Asset Growth %	2.3%	-4.64%	11.62%	1.19%	1.49%	5.09%	5.39%	-0.2%	5.01%	-4.51%
Total Current Liabilities+	16.43B	15.46B	17.38B	20.38B	19.25B	21.3B	23.96B	24.19B	29.16B	28.35B
Accounts Payable	4.3B	4.63B	5.04B	5.31B	5.29B	6.18B	6.81B	7.33B	7.55B	22.93B
Days Payables Outstanding	146.57	145.62	160.91	161.89	158.95	184.06	209.29	211.81	208.72	647.56
Short-Term Debt	1.76B	1.27B	2.63B	4.82B	3B	3.45B	4.45B	2.32B	4.21B	4.34B
Deferred Revenue (Current)	0	0	0	0	252M	319M	264M	0	0	0
Other Current Liabilities	7.27B	6.45B	6.98B	7.66B	9.75B	10.61B	11.86B	11.57B	15.13B	64.08M
Current Ratio	1.62x	1.70x	1.41x	1.40x	1.75x	1.44x	1.42x	1.27x	1.46x	1.09x
Quick Ratio	1.20x	1.26x	0.98x	1.01x	1.32x	1.03x	1.05x	0.87x	1.14x	0.29x
Cash Conversion Cycle	183.72	156.09	173.36	179.49	188.98	166.69	162.65	164.4	139.57	-3.57
Total Non-Current Liabilities+	30.51B	26.11B	35B	33.25B	31.91B	29.92B	27.61B	27.92B	25.78B	26.74B
Long-Term Debt	16.78B	14.31B	21.99B	20.13B	19.75B	17.12B	14.86B	14.35B	11.79B	15.71B
Capital Lease Obligations	34M	20M	18M	987M	931M	1.84B	1.9B	1.75B	1.65B	1.47B
Deferred Tax Liabilities	2.29B	1.6B	3.41B	2.29B	1.77B	1.62B	1.84B	1.86B	2.17B	1.67B
Other Non-Current Liabilities	11.41B	10.18B	9.58B	9.84B	9.47B	9.34B	9B	9.96B	10.18B	7.9B
Total Liabilities	46.95B	41.57B	52.37B	53.63B	51.16B	51.21B	51.57B	52.11B	54.94B	55.1B
Total Debt+	18.58B	15.6B	24.64B	25.93B	23.68B	22.41B	21.21B	18.7B	17.91B	21.79B
Net Debt	8.31B	5.29B	17.71B	16.19B	9.76B	12.32B	8.48B	9.99B	10.46B	14.13B
Debt / Equity	0.32x	0.27x	0.42x	0.44x	0.37x	0.32x	0.28x	0.25x	0.23x	0.30x
Debt / EBITDA	1.89x	1.64x	2.75x	2.47x	1.33x	1.95x	1.60x	1.64x	1.65x	2.28x
Net Debt / EBITDA	0.84x	0.56x	1.98x	1.54x	0.55x	1.07x	0.64x	0.88x	0.97x	1.48x
Interest Coverage	16.35x	17.41x	9.61x	5.69x	32.76x	21.53x	26.41x	13.57x	11.65x	11.73x
Total Equity+	57.72B	58.24B	59.03B	59.11B	63.25B	69.03B	75.15B	74.35B	77.86B	71.71B
Equity Growth %	-0.83%	0.89%	1.37%	0.12%	7.01%	9.14%	8.87%	-1.06%	4.71%	-7.9%
Book Value per Share	22.43	23.17	23.67	23.65	25.23	27.56	30.02	29.59	31.11	29.38
Total Shareholders' Equity	57.55B	58.07B	58.88B	58.93B	63.11B	68.68B	74.78B	74.04B	77.51B	71.38B
Common Stock	2.58B	2.51B	2.5B	2.51B	2.52B	2.53B	2.52B	2.53B	2.53B	71.38B
Retained Earnings	51.48B	52.86B	53.11B	51.78B	60.15B	63.01B	66.73B	67.5B	0	0
Treasury Stock	-1.5B	-14M	-153M	-9M	-705M	-939M	-706M	-1.18B	-840M	0
Accumulated OCI	5B	2.71B	3.43B	4.51B	782M	3.55B	6.11B	4.88B	70.56B	0
Minority Interest	170M	169M	159M	174M	146M	350M	368M	313M	350M	334M

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	7.84B	7.38B	5.55B	7.74B	7.45B	10.52B	10.53B	10.26B	9.08B	10.75B
Operating CF Margin %	22.59%	20.37%	15.55%	20.58%	19.93%	26.86%	25.95%	24.65%	20.51%	23.01%
Operating CF Growth %	-12.13%	-5.86%	-24.83%	39.61%	-3.81%	41.25%	0.04%	-2.55%	-11.47%	18.38%
Net Income	4.71B	8.43B	4.31B	1.86B	12.31B	6.22B	8.37B	5.4B	5.5B	7.81B
Depreciation & Amortization	3.3B	3.69B	4.28B	7.45B	3.3B	3.35B	3.42B	3.78B	3.59B	3.21B
Stock-Based Compensation	250M	263M	284M	252M	0	244M	245M	0	0	0
Deferred Taxes	-542M	-909M	-727M	-1.75B	-221M	-356M	-578M	-1.23B	-802M	0
Other Non-Cash Items	-458M	-3.98B	-1.03B	355M	-7.62B	-349M	-225M	1.55B	1.42B	-273M
Working Capital Changes	828M	148M	-1.28B	-419M	-325M	1.41B	-707M	764M	-615M	0
Change in Receivables	168M	-529M	-35M	-462M	-134M	185M	-777M	-397M	-28M	0
Change in Inventory	-323M	-145M	-701M	-547M	-593M	-357M	-927M	-840M	-477M	0
Change in Payables	447M	577M	270M	169M	86M	451M	452M	402M	789M	0
Cash from Investing+	-2.51B	639M	-12.87B	-1.06B	3.59B	-7.3B	-2.08B	-6.2B	-4.41B	-2.45B
Capital Expenditures	-2.08B	-1.96B	-1.98B	-1.82B	-2.11B	-2.04B	-2.2B	-3.25B	-3.23B	-1.86B
CapEx % of Revenue	6%	5.4%	5.54%	4.83%	5.66%	5.22%	5.43%	7.82%	7.3%	3.98%
Acquisitions	-426M	-1.15B	-12.86B	-488M	5.03B	-5.59B	-858M	1.01B	-2.52B	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	206M	3.91B	2.1B	-94M	-113M	-68M	1.47B	-3.87B	1.35B	-589M
Cash from Financing+	-4.1B	-7.9B	3.93B	-4.19B	-6.49B	-7.06B	-5.82B	-8.05B	-5.76B	-8.21B
Debt Issued (Net)	2.29B	-2.3B	8.72B	-491M	-2.17B	-2.8B	-1.23B	-3.14B	-894M	0
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	0
Dividends Paid	-3.76B	-3.71B	-3.77B	-3.83B	-3.94B	-4.01B	-4.17B	-4.45B	-4.7B	0
Share Repurchases	-2.91B	-2.16B	-1.1B	-9M	-822M	-382M	-497M	-593M	-302M	0
Other Financing	273M	-15M	-91M	141M	441M	-48M	77M	-63M	-50M	-8.21B
Net Change in Cash	1.13B	42M	-3.39B	2.5B	4.49B	-3.82B	2.64B	-4.03B	-1.27B	216M
Free Cash Flow+	5.75B	5.42B	3.57B	5.93B	5.33B	8.48B	8.32B	8.64B	5.89B	8.89B
FCF Margin %	16.59%	14.97%	10.01%	15.75%	14.28%	21.64%	20.52%	20.76%	13.29%	19.03%
FCF Growth %	-6.39%	-5.77%	-34.17%	66.05%	-10%	58.93%	-1.82%	3.77%	-31.87%	51.07%
FCF per Share	2.24	2.16	1.43	2.37	2.13	3.38	3.32	3.44	2.35	3.64
FCF Conversion (FCF/Net Income)	1.66x	0.88x	1.29x	2.81x	0.61x	1.69x	1.26x	1.90x	1.63x	1.38x
Interest Paid	401M	347M	412M	379M	315M	334M	380M	559M	587M	0
Taxes Paid	2.1B	1.73B	2.06B	1.7B	2.05B	1.28B	2.45B	2.62B	3.29B	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	8.12%	14.52%	7.34%	4.66%	20.09%	9.41%	11.61%	7.22%	7.31%	10.45%
Return on Invested Capital (ROIC)	7.44%	6.72%	5%	3.01%	14.27%	7.9%	9.24%	6.22%	6.3%	5.46%
Gross Margin	69.16%	67.94%	67.95%	68.17%	67.46%	68.72%	70.71%	69.66%	70.18%	72.34%
Net Margin	13.57%	23.24%	12.07%	7.32%	32.9%	15.89%	20.64%	12.98%	12.55%	16.72%
Debt / Equity	0.32x	0.27x	0.42x	0.44x	0.37x	0.32x	0.28x	0.25x	0.23x	0.30x
Interest Coverage	16.35x	17.41x	9.61x	5.69x	32.76x	21.53x	26.41x	13.57x	11.65x	11.73x
FCF Conversion	1.66x	0.88x	1.29x	2.81x	0.61x	1.69x	1.26x	1.90x	1.63x	1.38x
Revenue Growth	-0.47%	4.4%	-1.5%	5.48%	-0.7%	4.83%	3.54%	2.61%	6.41%	5.49%

Sanofi (SNY) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare SNY vs Peers

vs MRK

vs PFE

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Sanofi (SNY) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare SNY vs Peers

vs MRK

vs PFE

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios